JUDICIALIZATION OF ACCESS TO ANTINEOPLASIC AGENST IN ONCOLOGY SECTOR AT UFPEL HOSPITAL SCHOOL

Authors

  • Suelen de Mattos Cervi Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas - UFPel
  • Rosiane Mastelari Martins Setor de Oncologia, Hospital Escola da Universidade Federal de Pelotas
  • Roberta Socoowski Britto Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas
  • Paulo Maximiliano Corrêa Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas
  • Claiton Leoneti Lencina Universidade Federal de Pelotas

DOI:

https://doi.org/10.21527/2176-7114.2020.40.215-225

Keywords:

Antineoplastics, judicialization of health, oncology, pharmaceutical assistance

Abstract

Lawsuits regarding oncologic drugs are a growing reality in Brazil, causing great financial impact in the public administration. Due to the high cost associated with these drugs, in addition to the high complexity of the treatment, an insightful technical analysis is necessary to ensure the efficacy of the treatment, as well as the justifiable use of public money. The goal of this work was to analyze the profile of the lawsuit demands answered in the oncology sector of the UFPel School Hospital, along with the financial impact of these lawsuits to the public coffers. From January of 2017 to August of 2019 the oncology sector complied with 146 judicial decisions, with a total cost of nearly R$ 11,439,544.00 to the public coffers. In descending order, the drugs that were judicially demanded more often were: bortezomib, abiraterone, bevacizumab, trastuzumab, rituximab and pazopanib; being multiple myeloma, prostate cancer, colorectal cancer, breast cancer and kidney cancer the most prevalent malignancies. It is made evident that the effects are negative for the public administration as it generates budgetary and financial imbalances. However, this work points towards problems involved in the process, as well as strategies that can possibly be applied in short and long term by federative, judiciary and assistance entities, in order to minimize the negative consequences of the judicialization while ensuring to the citizen all their rights determined by law.

Published

2020-11-04

How to Cite

Cervi, S. de M., Martins, R. M., Britto, R. S., Corrêa, P. M., & Lencina, C. L. (2020). JUDICIALIZATION OF ACCESS TO ANTINEOPLASIC AGENST IN ONCOLOGY SECTOR AT UFPEL HOSPITAL SCHOOL. Context and Health Journal, 20(40), 215–225. https://doi.org/10.21527/2176-7114.2020.40.215-225

Issue

Section

Ciências Farmacêuticas & Saúde